| Outcome Measures: |
Primary: Change in Kidney Transplant Function From 2 Weeks Post Transplant Through 12 Months Post Transplant, change in the mean eGFR from the baseline (2 weeks post transplant), 3 months (post transplant) , and 12 months (post transplant)., 2 weeks post transplant through 12 months post transplant | Secondary: Change in Subpopulations of T Cells From 2 Weeks Post Transplant Through 12 Months Post Transplant, Blood, urine and kidney tissue analysis via serial flow cytometric immunophenotyping (includes regulatory T and B cell populations as well as immune functions)., Measured at 2 weeks post transplant, 3 months post transplant, 12 months post transplant|Number of Participants With Acute Rejection at 3 Months and 12 Months Post-Transplant, Acute rejection of kidney transplant is determined via biopsy., Measured at 3 months post transplant, 12 months post transplant|Number of Participants With Graft Loss at 3 Months and 12 Months Post-Transplant, Graft loss is determined via biopsy., Measured at 3 months post transplant, 12 months post transplant|Number of Subjects Deceased at at 3 Months and 12 Months Post-Transplant, Subject survival status is continually monitored via routine follow-up visits., Through 12 months post transplant|Number of Participants With Change in Allograft Immunohistopathology Profile, Tissue analysis via immunohistopathological staining and microscopic examination Moderate acute tubular necrosis =\> presence of focal coagulative necrosis or infarction on histopathologic examination Arteriolar hyalinosis grade 2 means: Replacement of degenerated smooth muscle cells by hyaline deposits in more than 1 arteriole, without circumferential involvement Global glomerulosclerosis \>grade 2, means glomerulosclerosis affecting more than 50% of glomeruli in the biopsy sample IFTA : Interstitial fibrosis and tubular atrophy: Inflammation in 26% to 50% of scarred cortical parenchyma, Measured at 3 months post transplant, 12 months post transplant
|
